Infection is a common cause of morbidity and mortality in the context of LBCL therapy.44, 45 Primary granulocyte colony-stimulating factor (G-CSF) prophylaxis and antimicrobial prophylaxis should be considered for all patients.46 Neutropenic prophylaxis with fluoroquinolone may be considered - informed by local microbiological guidance - for example in patients with additional risk factors for infection. The gene discussed is CSF3; the disease is infection.